Farmas USA

kubattaaaaa que lo de dormir no es sanooooooo ja,ja!

;))))

Ya veo ya :)!.
Yo guardo las horas para cuando demos un pelotazo gordo con la farma adecuada y nos retiramos :P

Alguien se enfadó con el Bastardo....

Yo, en la habitación de hotel que me paga Blackrock

Juas, pedazo de choza!! A disfrutarla!!

ACTC

No hay datos hoy finalmente en el English Journal of Medicine (al menos la versión en papel), así que hoy puede pronunciarse la corrección iniciada ayer tras el subidón. Pero ya llegará. Y el lunes: http://www.youtube.com/watch?feature=player_embedded&v=Mf8BYcUXWow

Y me encuentro el siguiente mensaje de una fuente muyyy fiable:

The Phase 2/3 Pivotal Trial Paper Work have already been submitted to the FDA, the Phase 1/2 Trial have been Terminated and preliminary verbal exchanges have indicated that the Application will be approved.

The Doctors were formally allowed to speak provided they will not discuss "functional results" but since they can use terms like very very promising... instead of "remember we are in a Safety Phase 1", it is logical to assume that the "functional results" like the Progression of Disease, and Acuity Improvements were all homeruns.

Thus the NEJM publication dates... other than the NEJM identification... is now moot, that is as far as I am involve... because as this junction... I am only interested in whether all these data have been consolidated and provided to the BioPharmas.

Now on the BreakThrough Designation... this will probably be mentioned at the time that the PR for the Application Filing or the Application Approval for the Phase 2/3 Pivotal are announced in several sets of PRs.

Also, there will be a series of RPE related Peer Reviewed Articles on NEJM... and also a series of Mesenchymal Stem Cell Peer Reviewed Articles coming down in 2014... at least ten (10) on the MSCs and a continuing series on the RPEs until Compassionate Use is allowed and Commercial Approval is obtained. Thus, as far as ACTC is concerned... it will be in major publications monthly for years to come.

Y otro:

10 INADS for Dogs, 10 INADS as Pre-clinical for humans... One stone for two Birds.
10 Investigators at the University Level would want their own names in a Peer Reviewed Article as required by
the Culture/Traditions of the University. Thus you have a minimum set of 10 Peer Reviewed Articles for the INADS.

There are also 200 other indications for the RPEs, and you can bet that Schwartz and Lanza will have another for the MMD...

There will be one for the Corneal Transplants on the Rabbits...

A controlar ISCO y Biotime

Buen viaje y que tu KARMA sea positivo!
Ayer con el inicio de la correcion, ya recogí los primeros profits, de la que esperamos sea el inicio del despegue al cielo!!!
ACTC

Por cierto, "peazo" pantalones llevas puestos...(la foto te delata)

a que se dedica usted ana?? vaya chozita y menudo pais!!! en un futuro cercano veo actc he de mirar mas sobre ello pero puede ser el pelotazo del año